Business Development, Clinical Trial, and Biopharmaceutical Services
Biocept is dedicated to supporting its partners, collaborators and clients with our unique Target Selector™ CTC and ctDNA technology platforms for rare event detection and genetic characterization. Our CLIA-licensed and CAP-accredited laboratory combines a highly trained professional staff who are experienced in liquid biopsy assay development with innovative instrumentation for optimal test results and quality control.
Our Target Selector™ platforms provide flexibility for developing liquid biopsy assays with unique requirements for our pharma or biotechnology partners. This development can be performed in our CLIA laboratory. We focus on providing high-level, personalized service to our clients, addressing critical questions of interest to them including:
Our experience includes working with pharmaceutical companies, major cancer centers, CROs, diagnostic firms and other testing laboratories on projects of various types. We bring creativity, customization, and responsiveness to all of our projects, seeking to best address our clients’ needs and help improve outcomes. We offer superb flexibility when designing and structuring projects.
Our proprietary technologies are focused on CTC and CtDNA biomarker analysis. With expertise in both specimens, Biocept can utilize technologies such as Immunocytochemistry, FISH, PCR, and Next Generation Sequencing to analyze alterations in both protein and DNA– all from the same sample. Sample types could include blood, bone marrow, urine, cerebrospinal fluid or saliva.
Our technical team is experienced in all aspects of rare cell and cell-free DNA research and testing, and this core competency allows us to develop collaborations aligned with our clients’ goals and interests.
Please contact Mike Terry, Senior Vice President Commercial Operations, for more information at 858-320-8297 or via email at firstname.lastname@example.org.
How Biocept is Creating the Future
We’re building partnerships that redefine the boundaries of personalized cancer medicine.